热门资讯> 正文
Alvotech因积极数据支持武田Entyvio的生物仿制药而走高
2026-02-05 21:15
- Alvotech (ALVO) shares spiked ~3% in the premarket on Thursday after the Luxembourg-based biotech succeeded in a study designed to evaluate AVT80, its proposed biosimilar to Entyvio, a bowel disease therapy marketed by Takeda (TAK).
- Citing topline data, Alvotech (ALVO) said that its pharmacokinetic (PK) study for AVT80 met its primary endpoints. The trial named AVT80-GL-P01 was designed to compare single 108 mg/0.68 mL subcutaneous (SC) injections of AVT80 and Entyvio in healthy adults.
- According to the company, Entyvio—approved for ulcerative colitis and Crohn’s disease—generated $6.4B in global net revenue last year.
- Alvotech (ALVO) noted that, based on regulatory feedback, AVT80-GL-P01 meets expectations to demonstrate PK similarity of its Entyvio versions, AVT80 and AVT16, targeted at subcutaneous and intravenous administrations.
More on Alvotech, Takeda Pharmaceutical
- Takeda Tests New Highs, But Struggles To Find Entyvio Successor
- Takeda Pharmaceutical Company Limited (TAK) Q3 FY2025 Earnings Call Transcript
- Alvotech: Why FDA Delays Don't Break The Bull Case
- Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar
- Takeda Pharmaceutical Non-GAAP EPS of ¥428.00, revenue of ¥3411.2B; updates FY26 outlook
推荐文章
美股机会日报 | 止跌企稳！纳指期货盘前涨约0.5%，有分析称美股连遭重挫后或回升；亚马逊盘前大跌超8%
一周财经日历 | 事关降息！美国1月非农、CPI数据下周公布；恒指季检结果下周五揭晓
华尔街大多头漫谈黄金“黑天鹅”风险：马斯克实现太空采金，化身全球央行行长
避险情绪席卷市场 华尔街青睐的热门交易纷纷崩跌
华盛早报 | 无一幸免！美股、金银、加密货币与原油集体崩盘；南向资金爆买250亿港元！创约半年来新高；千问APP今日启动30亿免单
亚马逊股价盘后大跌近10%，巨额资本支出引发担忧
比特币暴跌带来124亿美元巨亏 Saylor的金融实验岌岌可危
2月6日外盘头条：比特币暴跌 亚马逊预计今年资本支出将达2000亿美元 交易员料美联储将比预期更早降息
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
